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In haematological malignancies acquired abnormalities
in chromatin structure are increasingly recognised as an
important mechanism of leukemogenesis. Hypermethylation
of promoter CpG islands results in the down-regulation of a
range of tumor suppressor and pro-apoptotic genes which is
plausibly linked with the acquisition of a neoplastic pheno-
type. Similarly, acquired changes in the acetylation and
methylation status of histones caused by distinct leukemia
fusion proteins result in transcriptional deregulation which
contributes to the disease phenotype in patients with Acute
Myeloid Leukaemia (AML) and myelodysplasia (MDS). It is
therefore of great interest that pharmacological agents such
as DNA methyltransferase inhibitors (DNMTI) and histone
deacetylase inhibitors (HDI) with the capacity to reverse
acquired chromatin abnormalities demonstrate significant
clinical activity in patients with high risk MDS and AML.
Indeed the activity of DNMTIs such as 5-azacitidine (AZA),
when administered alone or in combination with an HDI,
has led to their emergence as one of the most important
recent therapeutic advances in the management of MDS
and AML in the last two decades. It remains the case how-
ever that the molecular mechanism by which this new class
of agents exerts an anti-tumor effect remains unknown.
Critically the extent to which their clinical activity is depen-
dent on re-induction of epigenetically silenced tumour sup-
pressor or pro-apoptotic genes or whether their anti-tumor
effect is mediated through an alternative mechanism
remains unknown.
It is now clear that the acquired abnormalities in chro-
matin structure which characterise many malignancies
also result in reduced expression of a number of candidate
tumor antigens, including members of the cancer testis
antigen family such as MAGE-A1 and MAGE-A3. Impor-
tantly there is convincing evidence, in solid tumors and
haematological malignancies, that DNMTIs such as AZA
and 5-aza-2’-deoxycytidine (decitabine) up-regulate the
expression of epigenetically repressed putative tumor anti-
gens thereby potentially increasing tumor immunogenicity.
Furthermore AZA also increases the expression of HLA
Class 1 and co-stimulatory molecules such asCD80 and
CD86 on the surface of leukemic blasts. The observation
that demethylating agents may modulate a tumor-specific
immune response also suggest that epigenetic therapies
might be used to enhance the clinical activity of both auto-
logous and allogeneic immunotherapeutic strategies.
Studies from have previously demonstrated that up-
regulation of the minor histocompatibility antigen HA-1
on solid tumors by decitabine sensitises tumor cells to
recognition by HA-1 specific cytotoxic T lymphocytes and
there is a now compelling case to investigate further the
role of epigenetic agents as a priming agent in settings
such as peptide vaccination. Epigenetic therapies also hold
promise as a potential mechanism of selectively augment-
ing an immunologically mediated graft-versus-leukaemia
(GVL) effect after allogeneic stem cell transplantation. In
principle the ability of DNMTI to up-regulate the expression
of epigenetically silenced tumor antigens without concomi-
tantly increasing the expression of minor histocompatibility
antigens on skin, gut or liver offers the possibility of increas-
ing a GVL effect without a concomitant risk of GVHD. In
this context the recent demonstration that post-transplant
AZA, albeit at lower doses, is well-tolerated and induces a
CD8+ T cell response to candidate tumor antigens post-
transplant is of great interest and supports the further exam-
ination of AZA as post-transplant therapy.
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